Neoadjuvant capecitabine plus docetaxel ± trastuzumab therapy for recently diagnosed breast cancer:: phase II results

被引：0
|
作者：
Tripathy, D.
Moisa, C.
Gluck, S.
机构：
[1] Univ Texas SW Med Ctr, Dallas, TX USA
[2] Roche Labs Inc, Nutley, NJ USA
[3] Univ Miami, Miami, FL 33152 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S226 / S226
页数：1
相关论文
共 50 条
  • [41] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [42] Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis.
    Wildiers, H.
    Neven, P.
    Christiaens, M-R
    Fesneaux, G.
    Amant, F.
    Weltens, C.
    Smeets, A.
    van Limbergen, E.
    Debrock, G.
    Renard, V
    Paridaens, R.
    CANCER RESEARCH, 2009, 69 (02) : 335S - 335S
  • [43] Efficacy of neoadjuvant bevacizumab (Av), capecitabine (X), and docetaxel (T) for invasive breast cancer (BC): Phase II result
    Greil, R.
    Moik, M.
    Reitsamer, R.
    Ressler, S.
    Stoll, M.
    Namberger, K.
    Menzel, C.
    Mlineritsch, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer
    Haley, B. B.
    Ashfaq, R.
    DeHaas, M.
    Ramaswami, A.
    Sikder, K.
    Tripathy, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Phase II study of neoadjuvant docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC)
    Perez-Manga, G.
    Mendez, M.
    Palomero, M. I.
    Quiben, R.
    Belon, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy
    Soley Bayraktar
    Melanie Royce
    Lisette Stork-Sloots
    Femke de Snoo
    Stefan Glück
    Medical Oncology, 2014, 31
  • [47] Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy
    Bayraktar, Soley
    Royce, Melanie
    Stork-Sloots, Lisette
    de Snoo, Femke
    Glueck, Stefan
    MEDICAL ONCOLOGY, 2014, 31 (10) : 1 - 7
  • [48] Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer
    Tuxen, Malgorzata K.
    Cold, Soeren
    Tange, Ulla B.
    Balslev, Eva
    Nielsen, Dorte L.
    ACTA ONCOLOGICA, 2014, 53 (10) : 1440 - 1445
  • [49] Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer
    Mrozek, Ewa
    Ramaswamy, Bhuvaneswari
    Young, Donn
    Rhoades, Chris A.
    Kendra, Kari
    Allen, Joan
    Moore, Tim
    Hauger, Marsha
    Watson, Holly
    Merriman, Nancy
    Nadella, Padma
    Villalona-Calero, Miguel
    Shapiro, Charles L.
    CLINICAL BREAST CANCER, 2006, 7 (02) : 141 - 145
  • [50] A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer
    Sehwan Han
    Sung Bae Kim
    Sung S. Kang
    Woo C. Noh
    Nam S. Paik
    Eil S. Chang
    Jae-Ryong Kim
    Sook-Hyun Lim
    Hee-Suk Park
    Breast Cancer Research and Treatment, 2006, 98 : 57 - 61
12345